Cancer
Cancer Ongoing 2020 Florida

LU003

A BIOMARKER-DRIVEN PROTOCOL FOR PREVIOUSLY TREATED ALKPOSITIVE NON-SQUAMOUS NSCLC PATIENTS: THE NCI-NRG ALK PROTOCOL

Trial overview

Disease
Breast cancer treatment and diagnosis
Topic
LU003
Description
Primary Objective • To assess whether ALK kinase domain mutations (G1202/C1156Y /I1171/L1196/ V1180/ F1174/ compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. • To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients • To evaluate objective responses of patients with specific genetic alterations (ALKL1198F/MET double mutation or high-level MET gene amplification) treated with crizotinib.
Physicians

Dr. Mohammad Jahanzeb

MD, FACP, FASCO

Medical Oncologist

Works at 3 centers.

Dr. Edgardo Santos

MD

Medical Oncologist

Works at 3 centers.